Sugi Predict

Sugi Predict / Compounds / SCHEMBL29761728

SCHEMBL29761728

SCHEMBL29761728

CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CS)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C

nearest known ligand 0.61

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CALCR P30988 4/20 0.61
▸ C5AR1 P21730 2/20 0.61
▸ APLNR P35414 1/20 0.59
▸ F2 P00734 4/20 0.56
▸ NPY2R P49146 5/20 0.56
▸ NPY4R P50391 5/20 0.56
▸ NPY5R Q15761 5/20 0.56
▸ NPY1R P25929 4/20 0.56
▸ EPHA2 P29317 1/20 0.55
▸ GLP1R P43220 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377908 0.96 C5AR1 (0.63) CALCRC5AR1APLNRF2NPY2R
SCHEMBL30880872 0.90 C5AR1 (0.60) CALCRC5AR1APLNRF2NPY2R
SCHEMBL31691539 0.89 APLNR (0.61) CALCRC5AR1APLNRF2NPY2R
SCHEMBL38661696 0.89 APLNR (0.57) CALCRC5AR1APLNRF2NPY2R
SCHEMBL29569693 0.88 AGTR1 (0.62) CALCRC5AR1APLNRF2
SCHEMBL31691514 0.88 APLNR (0.62) CALCRC5AR1APLNRF2NPY2R
SCHEMBL30932059 0.88 NPY2R (0.68) CALCRF2NPY2RNPY4RNPY5R
SCHEMBL30932084 0.88 NPY2R (0.68) CALCRF2NPY2RNPY4RNPY5R
SCHEMBL30932056 0.88 NPY2R (0.68) CALCRF2NPY2RNPY4RNPY5R
SCHEMBL30932058 0.88 NPY2R (0.68) CALCRF2NPY2RNPY4RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136987-A1 CHANNEL MODULATORS INFLAMMX THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4491184-A2 CHANNEL MODULATORS Auckland Uniservices Limited (NZ) 2025-01-15 — — EP disclosed
EP-3183346-B1 CHANNEL MODULATORS AUCKLAND UNISERVICES LTD (NZ) 2024-10-23 — — EP disclosed
US-20230174980-A1 CHANNEL MODULATORS INFLAMMX THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-11401516-B2 Channel modulators AUCKLAND UNISERVICES LIMITED (NZ) 2022-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174980-A1 CHANNEL MODULATORS GJB2, GJA1, P2RX2 CALCR 685/4885C5AR1 1984/4885APLNR 716/4885
US-11401516-B2 Channel modulators GJB2, GJA1, P2RX2 CALCR 685/4885C5AR1 1984/4885APLNR 716/4885
US-20250136987-A1 CHANNEL MODULATORS GJB2, GJA1, P2RX2 CALCR 685/4885C5AR1 1984/4885APLNR 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback